Aeternum Health Appoints New CEO and CFO; Employment Terms Disclosed

What Happened Aeternum Health, Inc. filed an 8‑K reporting it entered into employment agreements to appoint Josua Oosthuizen as CEO (agreement dated July 31, 2026) and Pieter Scholtz as CFO (agreement dated August 8, 2026). Mr. Oosthuizen will serve a two‑year term with a $240,000 annual base salary, an annual bonus opportunity of up to 60% of base salary, and milestone cash bonuses ($200,000 each) tied to reaching US GAAP-based average monthly revenues of $3M, $6M, $9M and $12M (each measured as trailing three‑month averages). Mr. Scholtz will serve two years with a $165,000 annual base salary and an annual bonus at management’s discretion. The company issued a press release on August 4, 2026 announcing the CEO hire.

Key Details

• CEO Josua Oosthuizen: $240,000 base salary; up to 60% annual bonus; four milestone cash bonuses of $200,000 each at $3M/$6M/$9M/$12M average monthly revenues (trailing 3 months).
• CFO Pieter Scholtz: $165,000 base salary; bonus discretionary by management; two‑year term.
• Severance for CEO: if terminated for any reason other than voluntary resignation, Mr. Oosthuizen receives accrued benefits, continuation of base salary through the remainder of the two‑year term (paid monthly), and acceleration of share awards to be exercisable until the earlier of one year post‑termination or the option’s original term.
• Backgrounds: Oosthuizen (age 41) has project-management and capital-project experience in mining and isotope-enrichment projects; Scholtz (age 63) is a Chartered Accountant (SA) with 30+ years in finance, governance and treasury roles across multiple African markets.

Why It Matters Leadership hires and the disclosed compensation create clear incentives and potential cash obligations tied to revenue growth. The CEO’s milestone bonuses directly link pay to scaled revenue milestones, which signals management’s focus on growing top-line results. The CEO severance provisions (salary continuation and accelerated equity) represent contingent cash/equity considerations investors should note when assessing corporate governance and potential future cash needs. The addition of experienced operational and financial executives may impact execution and reporting, but the filing contains only the contract terms and background—no forecasts or operational guidance were provided.